Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
<h4>Background</h4>Visceral leishmaniasis (VL) is one of the most neglected tropical infectious diseases. It is fatal if left untreated. The objective of this study was to assess the efficacy and safety of 17-day injections of combined regimen of sodium stibogluconate and paromomycin (SS...
Guardado en:
Autores principales: | Aschalew Tamiru, Rezika Mohammed, Saba Atnafu, Girmay Medhin, Asrat Hailu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f95ac388400044ab8793649b60e58e03 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
por: Majed Altareb, et al.
Publicado: (2021) -
Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
por: Tiget Ayelgn Mengstie, et al.
Publicado: (2021) -
A Novel Mg–CaMgSn Master Alloy for Grain Refinement in Mg–Al-Based Alloys
por: Jianyue Zhang, et al.
Publicado: (2021) -
Ag-Mg antisite defect induced high thermoelectric performance of α-MgAgSb
por: Zhenzhen Feng, et al.
Publicado: (2017) -
Acute kidney injury in patients with Visceral Leishmaniasis in Northwest Ethiopia.
por: Workagegnehu Hailu, et al.
Publicado: (2021)